View
218
Download
2
Embed Size (px)
Citation preview
Pathophysiology of Heme Synthesis
Beth A. BouchardBIOC 212: Biochemistry of Human Disease
Spring 2006
HEME-CONTAINING PROTEINS
Hemoglobin
Myoglobin
Cytochromes
Catalase
Some peroxidases
STRUCTURE OF HEME
An Overview of Iron MetabolismGut
Blood
Cells
• Low pH of stomach solubilizes Fe-containing ionic compounds.• Fe transporters facilitate absorption into blood stream
• Fe3+ ions are bound and chelated by Transferrin (Tf).• Transferrin transports Fe to tissues
•Maintains solubility•Keeps Fe ions unreactive
• Transferrin endocytosis is receptor-mediated (TfR)• Endocytosis results in Fe3+ release• Fe is distributed to topologically distinct regions of the cell via Fe transporter and/or channels (?)
• Usage: Protein components (Heme)• Storage: Ferritin (Fe2+)• Toxicity
Roles of Iron in the Cell
Transferrin Receptors (TfR)
Fe(III)2-Tf Tf
Proteins: Catalysis Electron, oxygen transport Structural stabilization Sensor of Fe, ROS Formation of protein-bound radicals
Storage and Sequestration: FerritinFerritin
Toxicity: Oxidative stress
[Fe]
[Fe]
[Fe]
Iron Control of Translation
• IREs are found in the 5’-UTR or the 3’-UTR of mRNAs
• Regulate mRNA translation via IRBP
• Decreased cellular iron levels: – IRBP is free of iron and can therefore,
interact with the IREs in the 3'-UTR of the transferrin receptor (TfR) mRNA, which prevents its degradation.
– IRBP binds to the IRE in the 5’-UTR of the ferritin mRNA preventing its translation.
• Increased cellular iron levels: – IRBP binds iron and cannot interact with
the IREs in the TfR mRNA resulting in an increase in its degradation.
– IRBP cannot bind to the IRE in the ferritin mRNA allowing for its translation.
IRE
STRUCTURE OF HEME
• Ferrous iron (Fe2+)
• Protoporphyrin IX: contains 4 pyrrole rings linked together by methenyl bridges
Heme
8
8
Succinyl CoA
Glycine**
HEME SYNTHESIS
** Amino acid (building blocks of protein) synthesized in your body
Heme synthesis
HEME SYNTHESIS
HEME SYNTHESIS: Red blood cells
•85% of total heme synthesis occurs in red blood cells (RBC)
•Ceases when RBC’s mature
•Erythroid-specific ALA synthase is regulated by an IRE in the mRNA – binding of IRBP inhibits mRNA translation
Heme stimulates hemoglobin synthesis in reticulocytes
HCI = heme controlledinhibitor
Reduced initiation of translation
***
In RBCS, heme synthesis is also regulated at the level of the en-zymes ferrochelatase* and porphobilinogen deaminase**
HEME SYNTHESIS: Liver
•The liver is the main non-RBC source of heme synthesis
•Heme produced in the liver is used mainly for the synthesis of the cytochrome P450 class of enzymes that are involved in detoxification
Regulated at level of ALA synthase: Formation of 5-ALA is the rate-limiting step in heme synthesis in the liver
Formation of 5-aminolevulinate (5-ALA)
5-ALA
5-ALA is formed in the mitochondria and transported to the cytoplasm
Regulation of ALA Synthase
Level of enzyme synthesis
Enzyme synthesis, as well as its transport to the mitochondria, is inhibited by elevated levels of
heme and hemin, the Fe3+ oxidation product of heme
Enzyme synthesis is upregulated by a large number of drugs including barbiturates, steroids with a 4,5 double bond (e.g. testosterone) and some oral contraceptives: These drugs are metabolized by the microsomal cytochrome P450 mono-oxygenase system, a heme- containing protein.
Level of enzyme activity
Heme and hemin inhibit ALA synthase activity
Requires pyridoxal phosphate (Vitamin B6) as a coenzyme
Disorders of Heme Synthesis
• Acquired: Lead poisoning
• Congenital: Porphyrias
• Deficiency of heme has far-reaching effects (hemoglobin, cytochromes, etc.)
LEAD TOXICITY
Symptoms Irritibility Poor appetite Lethargy Abdominal pain (with or Sleeplessness without vomiting) Headaches Constipation
Pathophysoiology Binds to any compound with a sulfhydryl group Inhibits multiple enzyme reactions including
those involved in heme biosynthesis (PBG synthase & ferrochelatase)
One symptom of lead toxicity is increases in 5-ALA without concomitant increases in PBG
HEME SYNTHESIS (CONT.)
lead
Vitamin B6
PORPHYRIAS
A group of rare disorders caused by deficiencies of enzymes of the heme biosynthetic pathway
The majority of the porphyrias are inherited in a autosomal dominant fashion - thus, affected individuals have 50% normal levels of the enzymes, and can still synthesize some heme
Affected individuals have an accumulation of heme precursors (porphyrins), which are toxic at high concentrations
Attacks of the disease are triggered by certain drugs, chemicals, and foods, and also by exposure to sun
Treatment involves administration of hemin, which provides negative feedback for the heme biosynthetic pathway, and therefore, prevents accumulation of heme precursors
Scriver et al., The Metabolic & Molecular Basis of Inherited Disease, 8th edition, 2001.
ACUTE INTERMITTENT PORPHYRIA
Hepatic, autosomal dominant
Caused by a deficiency in porphobilinogen deaminase, which is involved in the conversion of porphobilinogen (PBG) to uroporphyrinogen III
PBG, uroprophryin, and 5-ALA accumulate in the plasmaand the urine
Patients have neuropyschiatric symptoms and abdominal pain (neurovisceral)
PORPHYRIA CUTANEA TARDA
Most common porphyria
Hepatic, autosomal dominant
Disease is caused by a deficiency in uroporphyrinogen decarboxylase, which is involved in the conversion of uroporphyrinogen III to coproporphyrinogen III
Uroporphyrinogen accumulates in urine
Patients are photosensitive (cutaneous photosensitivity)Accumulation of porphyrinogens results in their conversion to porphyrins by light
Porphyrins react with molecular oxygen to form oxygen radicals
Oxygen radicals can cause severe damage to the skin